We’re delighted to add our latest Educational Series titled: Epilepsy in Focus: Navigating Status Epilepticus, Treatment Advances, and the Role of ZYAMIS.
This educational review outlines the burden of status epilepticus on the Australian patient population and summarises the rescue treatment options currently used in clinical practice in light of the August 2024 listing of ZYAMIS (intrabuccal midazolam formulation) on the Pharmaceutical Benefits Scheme for the treatment of generalised convulsive status epilepticus in patients over 1 year of age. It also includes guiding commentary from Professor Terence O'Brien, Chair of Medicine (Neurology) and Head of the School of Translational Medicine at Monash University. He also serves as Program Director of Alfred Brain and Deputy Director of Research at Alfred Health.
Please login below to download this issue (PDF)